Sandoz Inc. issued the recall for losartan potassium hydrochlorothiazide tablets because they could be tainted with an impurity known as N-nitrosodiethylamine (NDEA), which has been labeled as a “known human carcinogen” (cancer-causing substance) by the World Health Organization’s International Agency for Research on Cancer (IARC).

Losartan affected by the recall are 100 milligram/25 milligram tablets with the lot number JB8912. The contaminated medication was not distributed before Oct. 8, according to the FDA.

If you take losartan, you should talk to your doctor before quitting the drug, as stopping it abruptly could have adverse health effects of its own, the agency said.


Posted by Ray Simon

Ray Simon is a veteran copywriter with more than a decade's worth of experience in the field. He studied journalism at Vanderbilt University, graduating Cum Laude in 2007. Ray currently specializes in writing content and news articles for independent publications.